sumifilam

From Aaushi

Jump to navigation Jump to search

^[1]^[2]

Indications

investigational agent for treatment of Alzheimer's disease

Dosage

50 mg or 100 mg BID

Mechanism of action

binds to filamin A Clinical trials.
phase 2b trial^[1]
improves entire panel of validated biomarkers
improves episodic memory & spatial working memory vs placebo (46-17%)

Notes

investigator indicted on charges of research fraud used to obtain NIH funding^[2]

More general terms

Alzheimer's agent

References

↑ ^1.0 ^1.1 Cassava Sciences. Sept 14, 2020 Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer's Disease. https://www.globenewswire.com/news-release/2020/09/14/2092861/0/en/Cassava-Sciences-Announces-Final-Results-of-a-Phase-2b-Clinical-Study-of-Sumifilam-in-Patients-with-Alzheimer-s-Disease.html
↑ ^2.0 ^2.1 Bush E Scientist behind Alzheimer's drug in late-stage trials is indicted on charges of research fraud. Science News. June 28, 2024 https://www.nbcnews.com/science/science-news/scientist-alzheimers-drug-candidate-indicted-charges-research-fraud-rcna159537

Retrieved from "https://aaushi.info/w/index.php?title=A56748&oldid=1212052"

↑ Back to top